Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Bleecker, Eugene R, Prof, FitzGerald, J Mark, Prof, Chanez, Pascal, Prof, Papi, Alberto, Prof, Weinstein, Steven F, Prof, Barker, Peter, PhD, Sproule, Stephanie, MMath, Gilmartin, Geoffrey, MD, Aurivillius, Magnus, MD, Werkström, Viktoria, MD, Goldman, Mitchell, MD
Published in The Lancet (British edition) (29.10.2016)
Published in The Lancet (British edition) (29.10.2016)
Get full text
Journal Article
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
FitzGerald, J Mark, Dr, Bleecker, Eugene R, Prof, Nair, Parameswaran, Prof, Korn, Stephanie, MD, Ohta, Ken, MD, Lommatzsch, Marek, Prof, Ferguson, Gary T, MD, Busse, William W, Prof, Barker, Peter, PhD, Sproule, Stephanie, MMath, Gilmartin, Geoffrey, MD, Werkström, Viktoria, MD, Aurivillius, Magnus, MD, Goldman, Mitchell, MD
Published in The Lancet (British edition) (29.10.2016)
Published in The Lancet (British edition) (29.10.2016)
Get full text
Journal Article